PTC Therapeutics
PTCT
56.42
-1.91
-3.27%
PTC Therapeutics
US · PTCT
#2071 by market cap
Listed 1970
56.42
-1.91
-3.27%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130Market Newswire · 2026/8/13
-
Rating change
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy RatingMarket Newswire · 2026/10/14
-
Rating change
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $90 to $112Market Newswire · 2026/10/31
-
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $122Market Newswire · 2026/11/2
-
Rating change
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $109Market Newswire · 2026/9/2
-
UBS Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/10/30
-
Rating change
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $112Market Newswire · 2026/10/30
-
Rating change
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $77Market Newswire · 2026/10/30
-
Rating change
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $137Market Newswire · 2026/9/22
-
Rating change
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109Market Newswire · 2026/10/19
-
Rating change
UBS Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $90Market Newswire · 2026/10/15
-
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $92Market Newswire · 2026/11/6
-
Rating change
Raymond James Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $106Market Newswire · 2026/10/20
-
Citi Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109Market Newswire · 2026/11/2
-
Rating change
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Cuts Target Price to $75Market Newswire · 2026/10/7
-
Rating change
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $96Market Newswire · 2026/8/13
-
Rating change
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $122Market Newswire · 2026/8/14
-
Rating change
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy RatingMarket Newswire · 2026/10/9
-
Rating change
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/8/31
-
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $92Market Newswire · 2026/11/2
-
Rating change
Goldman Sachs Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $70Market Newswire · 2026/7/31
-
Rating change
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $106Market Newswire · 2026/7/31
-
Rating change
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/8/4
-
Rating change
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $122Market Newswire · 2026/10/7
-
Rating change
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109Market Newswire · 2026/8/13
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
PTC Therapeutics discussion 0 comments